Strontium Ranelate
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Using no additional skills — this is a direct report-writing task with an explicit template already specified in the prompt.
Strontium Ranelate: From Osteoporosis to Heparin Cofactor 2 Deficiency
One-Sentence Summary
Strontium ranelate was historically used in the management of severe osteoporosis, though this evidence pack contains no verified original-indication or mechanism-of-action data. The TxGNN model predicts a possible association with Heparin Cofactor 2 Deficiency, but currently no clinical trials and no published literature support this direction — this is a pure computational signal with a blocking safety data gap.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (original_indications is empty). Strontium ranelate is publicly known to have been indicated for severe osteoporosis in postmenopausal women/men at high fracture risk — this is background context, not sourced from the evidence pack |
| Predicted New Indication | Heparin Cofactor 2 Deficiency |
| TxGNN Prediction Score | 99.81% (rank 2529 of full candidate list) |
| Evidence Level | L5 (model prediction only — no clinical trials or literature identified) |
| UK Market Status | Not marketed (Not marketed) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this candidate (original_moa: [Data Gap]). Based on general published information, strontium ranelate acts on bone remodelling by substituting for calcium in the bone mineral matrix, promoting osteoblastic activity while reducing osteoclastic activity. No documented pharmacological pathway connects this bone-remodelling mechanism to coagulation factor physiology.
The top five TxGNN predictions for this drug are notably clustered around coagulation/thrombophilia disorders (heparin cofactor 2 deficiency, antithrombin deficiency type 2, factor V excess with spontaneous thrombosis, thrombophilia) plus one unrelated ophthalmic prediction (severe nonproliferative diabetic retinopathy). This clustering pattern may reflect a genuine but undocumented biological signal, or it may reflect a knowledge-graph artefact (e.g. shared node connections unrelated to true pharmacology). The repurposing_rationale fields in the evidence pack are still marked "pending", meaning no mechanistic linkage or similarity-to-original analysis has yet been generated by the pipeline itself.
Given the absence of both a confirmed original indication and a confirmed MOA, no clinically credible rationale can currently be constructed for this prediction. It should be treated as a raw signal requiring expert pharmacological review, not an evidence-supported hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
No UK marketing authorisations are on record for this product (total_licenses: 0, market_status: Not marketed / Not marketed). No licence table can be produced from this evidence pack.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note on data completeness: this evidence pack flags TFDA label warnings/contraindications (DG001) as a Blocking data gap, explicitly noting that the initial safety screen (S1) cannot proceed without it. No key warnings, contraindications, or drug interaction data are currently available for review.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or literature evidence for this predicted indication, no confirmed mechanism of action, and no marketing presence in the UK to anchor a safety baseline. Most critically, product safety labelling data is marked as a Blocking gap, meaning this candidate cannot legitimately enter safety pre-screening in its current state.
To proceed, the following is needed:
- TFDA/MHRA product label (warnings, contraindications) — currently blocking
- Confirmed mechanism of action from DrugBank or SmPC
- Confirmation of original approved indication(s) with source citation
- Targeted literature/clinical trial search specifically for strontium ranelate and coagulation-related outcomes, to determine whether the clustering signal across the top 5 predictions reflects real pharmacology or a knowledge-graph artefact
- Given the drug’s UK “not marketed” status, confirmation of regulatory history (e.g. any past withdrawal or restriction) before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.